Vitrolife AB (publ) (FRA:VTFN)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.30B -27.8% |
| Revenue (ttm) | 303.46M -1.9% |
| Net Income | -437.28M |
| EPS | -3.30 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 20.16 |
| Dividend | 0.10 (1.06%) |
| Ex-Dividend Date | May 6, 2026 |
| Volume | 100 |
| Open | 9.02 |
| Previous Close | 8.49 |
| Day's Range | 9.02 - 9.56 |
| 52-Week Range | 7.46 - 13.66 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden. [Read more]
News
Vitrolife AB Earnings Call Transcript: Q3 2026
Q3 sales grew 6% organically, with strong Technologies growth and higher earnings per share. Restructuring advanced on plan, while China demand remained weak and 2027 launches are expected to build over time.
Vitrolife AB Quarterly report: Q3 2026
Vitrolife AB has published its Q3 2026 quarterly earnings report on October 22, 2026.
Vitrolife AB Slides: Q3 2026
Vitrolife AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
Vitrolife AB Slides: Pre-silent call presentation
Vitrolife AB has posted slides in relation to its latest quarterly earnings report, which was published on September 21, 2026.
Vitrolife AB Earnings Call Transcript: Q2 2026
Record Consumables revenue and improved profitability driven by strategic exits and cost discipline. Gross margin and EBITDA margins rose across all regions, while market softness in China and the Middle East weighed on growth. Share repurchase and dividend programs were announced.
Vitrolife AB Quarterly report: Q2 2026
Vitrolife AB has published its Q2 2026 quarterly earnings report on July 16, 2026.
Vitrolife AB Slides: Q2 2026
Vitrolife AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Vitrolife AB Slides: Pre-silent call presentation
Vitrolife AB has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Report from the Annual General Meeting of Vitrolife AB (publ)
The Annual General Meeting of Vitrolife AB (publ) was held today on Tuesday 5 May 2026. The Annual General Meeting resolved in accordance with all proposals presented by the Board and the Nomination C...
Vitrolife AB Earnings Call Transcript: Q1 2026
Organic growth reached 5% in local currencies, with strong North America and APAC performance offsetting Middle East declines. Gross margin hit 59.9%, and EBITDA margin was 31.1%. Innovation and restructuring are expected to further support profitability.
Vitrolife AB Quarterly report: Q1 2026
Vitrolife AB has published its Q1 2026 quarterly earnings report on April 23, 2026.
Vitrolife AB Slides: Q1 2026
Vitrolife AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Vitrolife AB (publ) - Interim report Q1, 2026: Strong growth in Consumables and Technologies
GOTHENBURG, Sweden, April 23, 2026 /PRNewswire/ -- First quarter Sales of SEK 807 (842) million, an increase of 5% in local currencies and 4% decrease in SEK. Sales per region, in local currencies,...
Notice of the Annual General Meeting of Vitrolife AB (publ)
GOTHENBURG, Sweden, April 1, 2026 /PRNewswire/ -- The Annual General Meeting of Vitrolife AB (publ), 556354-3452, will be held on Tuesday 5 May 2026 at 17:00 CEST at Elite Park Avenue Hotel, Kungsport...
Vitrolife AB Slides: Pre-silent call presentation
Vitrolife AB has posted slides in relation to its latest quarterly earnings report, which was published on March 20, 2026.
Vitrolife AB Earnings Call Transcript: Q4 2025
Q4 saw 6% organic growth (excl. discontinued business), led by strong Americas and APAC performance, but margins declined due to currency and mix effects. A restructuring in Genetic Services and targeted campaigns shaped results, with 2026 expected to bring normalized market conditions and a focus on profitable growth.
Vitrolife AB Annual report: Q4 2025
Vitrolife AB has published its Q4 2025 annual report on February 3, 2026.
Vitrolife AB Quarterly report: Q4 2025
Vitrolife AB has published its Q4 2025 quarterly earnings report on February 3, 2026.
Vitrolife AB Slides: Q4 2025
Vitrolife AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Vitrolife AB (publ) - Fourth quarter and full year report 2025
GOTHENBURG, Sweden, Feb. 3, 2026 /PRNewswire/ -- Fourth quarter Sales of SEK 891 (959) million, organic growth in local currencies excluding discontinued business* were 6%, 3% growth in local curren...
Invitation to Vitrolife Group's presentation of the fourth quarter and full year report 2025
GOTHENBURG, Sweden, Jan. 20, 2026 /PRNewswire/ -- Vitrolife AB (publ) will publish its fourth quarter and full year report 2025 on Tuesday, 3 February 2026 at 08:00 am CET. A conference call for inves...
Vitrolife AB Slides: FY 2026
Vitrolife AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on January 14, 2026.
Vitrolife AB Slides: Pre-silent call presentation
Vitrolife AB has posted slides in relation to its latest quarterly earnings report, which was published on December 18, 2025.
Vitrolife AB Slides: Group call with analysts presentation
Vitrolife AB has posted slides in relation to its latest quarterly earnings report, which was published on December 16, 2025.
Vitrolife AB Slides: Investor presentation
Vitrolife AB has posted slides in relation to its latest quarterly earnings report, which was published on November 18, 2025.